- Home
- CZNC vs ATAI Comparison
CZNC vs ATAI Comparison
Compare CZNC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- ATAI
- Stock Information
- Founded
- CZNC 1864
- ATAI 2018
- Country
- CZNC United States
- ATAI Germany
- Employees
- CZNC N/A
- ATAI N/A
- Industry
- CZNC Major Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- ATAI Health Care
- Exchange
- CZNC Nasdaq
- ATAI Nasdaq
- Market Cap
- CZNC 286.0M
- ATAI 282.6M
- IPO Year
- CZNC N/A
- ATAI 2021
- Fundamental
- Price
- CZNC $19.10
- ATAI $1.39
- Analyst Decision
- CZNC
- ATAI Strong Buy
- Analyst Count
- CZNC 0
- ATAI 3
- Target Price
- CZNC N/A
- ATAI $10.50
- AVG Volume (30 Days)
- CZNC 35.1K
- ATAI 1.3M
- Earning Date
- CZNC 04-23-2025
- ATAI 05-19-2025
- Dividend Yield
- CZNC 5.86%
- ATAI N/A
- EPS Growth
- CZNC 15.34
- ATAI N/A
- EPS
- CZNC 1.75
- ATAI N/A
- Revenue
- CZNC $108,114,000.00
- ATAI $308,000.00
- Revenue This Year
- CZNC $9.38
- ATAI $65.58
- Revenue Next Year
- CZNC $3.77
- ATAI N/A
- P/E Ratio
- CZNC $10.93
- ATAI N/A
- Revenue Growth
- CZNC 5.33
- ATAI N/A
- 52 Week Low
- CZNC $16.50
- ATAI $1.03
- 52 Week High
- CZNC $22.68
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- CZNC 47.86
- ATAI 46.46
- Support Level
- CZNC $18.75
- ATAI $1.29
- Resistance Level
- CZNC $19.39
- ATAI $1.54
- Average True Range (ATR)
- CZNC 0.53
- ATAI 0.09
- MACD
- CZNC 0.06
- ATAI -0.00
- Stochastic Oscillator
- CZNC 38.79
- ATAI 37.04
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.